Venlafaxine Dosing and Monitoring for Anxiety in Adults

Initial Dosing and Therapeutic Range

The American Academy of Child and Adolescent Psychiatry recommends starting venlafaxine at 75 mg once daily for extended-release formulation, which permits convenient single-dose administration due to its long elimination half-life 1, 2
The target dose for optimal anxiety control is 150-225 mg/day, which typically requires 2-4 weeks of titration to reach 3

Blood pressure and pulse should be monitored at baseline and during treatment, as venlafaxine causes dose-dependent increases in blood pressure 1, 2
Height and weight monitoring is also recommended 2
Patients should be watched for behavioral activation, agitation, hypomania, or suicidal thinking, particularly those ≤24 years old, as venlafaxine may carry greater suicide risk than other SNRIs 1, 2
Monitor for serotonin syndrome if the patient takes other serotonergic medications 3

Allow 4-6 weeks at therapeutic dose (150-225 mg/day) before assessing response 3
If <30% reduction in anxiety symptoms after adequate trial at 225 mg/day, consider switching to alternative first-line medication (SSRI or duloxetine) 3

Never stop venlafaxine abruptly due to high risk of discontinuation syndrome 1, 2
Taper gradually over 10-14 days minimum to minimize withdrawal symptoms 2
Use cross-tapering if switching to another medication 3

Nausea, dizziness, somnolence, insomnia, dry mouth, and asthenia are the most common adverse effects of venlafaxine 1
Diaphoresis, abdominal discomfort, decreased appetite, and weight loss may also occur 1

Consider combining venlafaxine with cognitive behavioral therapy for superior efficacy compared to medication alone 3

The American Academy of Family Physicians recommends starting venlafaxine at approximately 50% of the standard adult dose in older adults due to increased risk of adverse drug reactions 4
The American Academy of Family Physicians suggests that maintenance treatment with venlafaxine prevents relapse and recurrence when continued beyond the acute phase, with recurrence probability of 50% after the first episode, 70% after two episodes, and 90% after three episodes 4

According to the Annals of Internal Medicine, nausea is a common adverse effect of venlafaxine, and the medication has a higher incidence of nausea and vomiting compared to other SSRIs 5
The Annals of Internal Medicine also reports that sexual adverse events occur with venlafaxine, but at lower rates than with paroxetine, and that absolute rates of sexual dysfunction are likely underreported in clinical trials 5

Dialogues in Clinical Neuroscience states that therapeutic drug monitoring is useful for venlafaxine to control whether plasma concentrations are plausible for given doses and optimize response in nonresponders with low concentrations 6
Therapeutic drug monitoring is particularly valuable for suspected noncompliance, drug interactions, switching between generic and brand formulations, and pharmacogenetic variations, according to Dialogues in Clinical Neuroscience 6